GUAIFENESIN AND DEXTROMETHORPHAN HBR

N/A

Manufactured by CVS Pharmacy

244 FDA adverse event reports analyzed

Last updated: 2026-04-15

About GUAIFENESIN AND DEXTROMETHORPHAN HBR

GUAIFENESIN AND DEXTROMETHORPHAN HBR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by CVS Pharmacy. The most commonly reported adverse reactions for GUAIFENESIN AND DEXTROMETHORPHAN HBR include COVID-19, DYSPNOEA, DIARRHOEA, DISEASE RECURRENCE, ASTHENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GUAIFENESIN AND DEXTROMETHORPHAN HBR.

Top Adverse Reactions

COVID 1910 reports
DYSPNOEA10 reports
DIARRHOEA7 reports
DISEASE RECURRENCE7 reports
ASTHENIA6 reports
PAIN6 reports
PNEUMONIA6 reports
COUGH5 reports
FATIGUE5 reports
BLOOD PRESSURE INCREASED4 reports
DEHYDRATION4 reports
DRUG INEFFECTIVE4 reports
FALL4 reports
FEELING ABNORMAL4 reports
HEADACHE4 reports
NASOPHARYNGITIS4 reports
NAUSEA4 reports
PAIN IN EXTREMITY4 reports
WEIGHT DECREASED4 reports
CONFUSIONAL STATE3 reports
DEPRESSION3 reports
DIZZINESS3 reports
INFLUENZA LIKE ILLNESS3 reports
MALAISE3 reports
OFF LABEL USE3 reports
PARAESTHESIA3 reports
RENAL FAILURE ACUTE3 reports
SINUSITIS3 reports
URINARY TRACT INFECTION3 reports
ANAEMIA2 reports
ATRIAL FIBRILLATION2 reports
BALANCE DISORDER2 reports
BLOOD GLUCOSE INCREASED2 reports
BRONCHITIS2 reports
CARDIO RESPIRATORY ARREST2 reports
CHILLS2 reports
CHRONIC OBSTRUCTIVE PULMONARY DISEASE2 reports
COLITIS2 reports
COMPLETED SUICIDE2 reports
CONDITION AGGRAVATED2 reports
CONVULSION2 reports
DEEP VEIN THROMBOSIS2 reports
DRUG INTERACTION2 reports
FEELING HOT2 reports
FLUSHING2 reports
GASTROINTESTINAL DISORDER2 reports
HAEMORRHOIDS2 reports
HERNIA2 reports
HOSPITALISATION2 reports
HYPERSENSITIVITY2 reports
HYPOTENSION2 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION2 reports
MEMORY IMPAIRMENT2 reports
MULTIPLE ALLERGIES2 reports
OVERDOSE2 reports
PRODUCT DOSE OMISSION ISSUE2 reports
PRODUCT USE COMPLAINT2 reports
PRODUCT USE IN UNAPPROVED INDICATION2 reports
PRURITUS2 reports
PYREXIA2 reports
RETCHING2 reports
SEASONAL ALLERGY2 reports
SEPSIS2 reports
SWOLLEN TONGUE2 reports
THROAT TIGHTNESS2 reports
TREATMENT NONCOMPLIANCE2 reports
UNEVALUABLE EVENT2 reports
URTICARIA2 reports
VERTIGO2 reports
VIRAL INFECTION2 reports
5Q MINUS SYNDROME1 reports
ABDOMINAL HERNIA1 reports
ABNORMAL BEHAVIOUR1 reports
ABNORMAL DREAMS1 reports
ACCIDENTAL OVERDOSE1 reports
ADMINISTRATION SITE PAIN1 reports
ADMINISTRATION SITE SWELLING1 reports
AGEUSIA1 reports
ALLERGY TO ARTHROPOD STING1 reports
ANAPHYLACTIC REACTION1 reports
ANAPHYLACTIC SHOCK1 reports
ANHEDONIA1 reports
ARTERIAL OCCLUSIVE DISEASE1 reports
ARTHRALGIA1 reports
ARTHRITIS1 reports
ARTHROPOD BITE1 reports
BACK PAIN1 reports
BLOOD POTASSIUM DECREASED1 reports
BLOOD PRESSURE ABNORMAL1 reports
BLOOD PRESSURE DECREASED1 reports
BLOOD SODIUM DECREASED1 reports
BRONCHIECTASIS1 reports
BURNING SENSATION1 reports
CATHETER SITE ERYTHEMA1 reports
CATHETER SITE PAIN1 reports
CATHETER SITE RELATED REACTION1 reports
CATHETER SITE SWELLING1 reports
CEREBROVASCULAR ACCIDENT1 reports
CHEST DISCOMFORT1 reports
CHEST PAIN1 reports

Report Outcomes

Out of 90 classified reports for GUAIFENESIN AND DEXTROMETHORPHAN HBR:

Serious 47.8%Non-Serious 52.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female46 (56.8%)
Male35 (43.2%)

Reports by Age

Age 694 reports
Age 593 reports
Age 623 reports
Age 643 reports
Age 653 reports
Age 663 reports
Age 683 reports
Age 362 reports
Age 512 reports
Age 532 reports
Age 582 reports
Age 712 reports
Age 722 reports
Age 842 reports
Age 161 reports
Age 171 reports
Age 211 reports
Age 271 reports
Age 281 reports
Age 291 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with GUAIFENESIN AND DEXTROMETHORPHAN HBR?

This profile reflects 244 FDA FAERS reports that mention GUAIFENESIN AND DEXTROMETHORPHAN HBR. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for GUAIFENESIN AND DEXTROMETHORPHAN HBR?

Frequently reported terms in FAERS include COVID-19, DYSPNOEA, DIARRHOEA, DISEASE RECURRENCE, ASTHENIA, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures GUAIFENESIN AND DEXTROMETHORPHAN HBR?

Labeling and FAERS entries often list CVS Pharmacy in connection with GUAIFENESIN AND DEXTROMETHORPHAN HBR. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.